Position in PHVS
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$3
-$2,822 QoQ
Shares Held
100
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#125
of 125 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PHVS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Centerpoint Advisors, LLC holds $114,760 across 8 Biotechnology names. PHVS ranks #8 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
87 | $43,215 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
545 | $42,657 | |
| 3 | ARGX |
Argenx SE
|
30 | $27,833 | |
| 4 | GERN |
Geron Corp
|
300 | $384 | |
| 5 | NMRA |
Neumora Therapeutics, Inc.
|
220 | $374 | |
| 6 | YARW |
Yarrow Bioscience, Inc.
|
7 | $227 | |
| 7 | RNA |
Atrium Therapeutics, Inc.
|
5 | $67 | |
| 8 | PHVS |
Pharvaris N.V.
This page
|
100 | $3 |
All Filings in PHVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3 | 100 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $2,825 | 100 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $2,775 | 100 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $2 | 100 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $2 | 100 | Shares | Sole | 2025-08-01 | |
| No filing history on record for this holder in this stock. | ||||||